<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A
(Amendment No. 1)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 1996
-----------------
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________________ to _________________
Commission file number 0-11103
-------
CENTOCOR, INC.
-----------------------------
(Exact name of registrant as specified in its charter)
Pennsylvania 23-2117202
- ----------------------------------- ------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
200 Great Valley Parkway, Malvern, PA 19355-1307
- ---------------------------------------- ----------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (610) 651-6000
--------------
Securities registered pursuant to Section 12(b) of the Act: None.
----
Securities registered pursuant to Section 12(g) of the Act:
Series A Preferred Stock Purchase Rights
----------------------------------------
(Title of Class)
Common Stock, par value $.01 per share
--------------------------------------
(Title of Class)
Warrants for the purchase of shares of Common Stock, par value $.01 per share*
- -----------------------------------------------------------------------------
(Title of Class)
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X . No .
------ ------
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [X]
The aggregate market value of the 69,053,050 shares of voting stock held by non-
affiliates of the Registrant as of February 18, 1997 was approximately
$2,572,226,113.
Common Stock outstanding at February 18, 1997: 69,589,250 shares.
DOCUMENTS INCORPORATED BY REFERENCE:
Portions of the following document are incorporated by reference in this
Report on Form 10-K:
Proxy Statement for the Annual Meeting of Shareholders held on May 14,
1997 -- Part III, Items 10, 11, 12 and 13.
*Includes Warrants issued in January 1992 which were registered pursuant to
Section 12(g) of the Securities Exchange Act of 1934 as part of Units, each Unit
consisting of one share of Callable Common Stock of Tocor II, Inc., one Series T
Warrant and one callable Warrant.
EXPLANATORY NOTE:
This Amendment No. 1 to the Registrant's Annual Report on Form 10-K for the
fiscal year ended December 31, 1996 is being filed solely for the purpose of
amending Part IV, Item 14 to refile Exhibit 10.24 to conform such exhibit to the
Registrant's confidential treatment request with respect to such exhibit.
<PAGE>
Part IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENTS SCHEDULES, AND REPORTS ON FORM 8-K
- --------------------------------------------------------------------------
a. Documents filed as part of the Report:
i. Financial Statements of Centocor Partners III, L.P.:
Balance Sheets, December 31, 1996 and 1995.
Statements of Operations for the Years Ended December 31, 1996,
1995 and 1994.
Statements of Cash Flows for the Years Ended December 31, 1996,
1995 and 1994.
Statements of Partners' Capital for the Years Ended December 31,
1996, 1995 and 1994.
Notes to Financial Statements.
Independent Auditors' Report.
ii. Financial Statement Schedules:
Schedule II - Valuation and Qualifying Accounts
Schedules, other than those listed above, have been omitted
because of the absence of conditions under which they are
required or because the required information is included in the
financial statements or the notes thereto.
1
<PAGE>
iii. Exhibits:
3.1 Restated Articles of Incorporation (incorporated by
reference to Exhibit 3.1 to Form S-1 Registration
Statement, File No. 2-80098).
3.2 Statement of Reduction of Authorized Shares filed
September 19, 1983 (incorporated by reference to
Exhibit 3.2 to Registrant's Annual Report on Form 10-
K for the year ended December 31, 1986).
3.3 Statement of Reduction of Authorized Shares filed
January 19, 1984 (incorporated by reference to
Exhibit 3.3 to Registrant's Annual Report on Form 10-
K for the year ended December 31, 1986).
3.4 Articles of Amendment filed April 18, 1984
(incorporated by reference to Exhibit 3.4 to
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1986).
3.5 Statement of Reduction of Authorized Shares filed
February 25, 1985 (incorporated by reference to
Exhibit 3.5 to Registrant's Annual Report on Form 10-
K for the year ended December 31, 1986).
3.6 Statement of Reduction of Authorized Shares filed May
6, 1985 (incorporated by reference to Exhibit 3.6 to
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1986).
3.7 Statement of Reduction of Authorized Shares filed
October 23, 1985 (incorporated by reference to
Exhibit 3.7 to Registrant's Annual Report on Form 10-
K for the year ended December 31, 1986).
3.8 Articles of Amendment filed April 16, 1987
(incorporated by reference to Exhibit 3.8 to
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1987).
3.9 Articles of Amendment filed April 21, 1988
(incorporated by reference to Exhibit 3.9 to
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1988) .
3.10 Articles of Amendment filed April 26, 1988
(incorporated by reference to Exhibit 3.10 to
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1988).
3.11 Statement Re Series A Preferred Stock filed October
11, 1988 (incorporated by reference to Exhibit 3.11
to Registrant's Annual Report on Form 10-K for the
year ended December 31, 1988).
3.12 Articles of Amendment filed April 13, 1990
(incorporated by reference to Exhibit 3.12 to
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1990).
2
<PAGE>
3.13 Articles of Amendment filed April 26, 1991
(incorporated by reference to Exhibit 3.13 to
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1991).
3.14 Statement of Correction filed October 16, 1991 to
Articles of Amendment filed April 26, 1991
(incorporated by reference to Exhibit 3.14 to
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1991).
3.15 By-Laws of Centocor, Inc. as amended October 30, 1992
(incorporated by reference to Exhibit 3.15 to
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1992).
4.1 Specimen Certificate for Common Stock (incorporated
by reference to Exhibit 4 to Amendment No. 1 to Form
S-1 Registration Statement, File No. 2-80098).
4.2 Rights Agreement between Centocor, Inc. and the First
National Bank of Boston as Rights Agent dated
September 26, 1988 (incorporated by reference to
Exhibit 4 to Registrant's Current Report on Form 8-K
dated September 26, 1988).
4.3 Form of Indenture between Centocor, Inc. and Chase
Manhattan Trustees Limited as Trustee Dated as of
October 16, 1991 (incorporated by reference to
Exhibit 4.3 to Form S-3 Registration Statement, Reg.
No. 33-44231).
4.4 Form of Debenture Issued to Purchasers of 6 3/4%
Convertible Subordinated Debentures Due October 16,
2001 (included in Exhibit 4.9) (incorporated by
reference to Exhibit 4.3 to Form S-3 Registration
Statement, Reg. No. 33-44231).
4.5 Form of Series T Warrant Issued to Purchasers of
Units, each Unit consisting of one share of Tocor II
Callable Common Stock, one Series T warrant to
purchase one share of Centocor Common Stock, and one
Callable warrant to purchase one share of Centocor
Common Stock (incorporated by reference to Exhibit
4.2 to Amendment No. 4 to Form S-1/S-3 Registration
Statement of Tocor II and Centocor, Reg. No. 33-
44072).
4.6 Form of Callable Warrant Issued to Purchasers of
Units, each Unit consisting of one share of Tocor II
Callable Common Stock, one Series T warrant to
purchase one share of Centocor Common Stock, and one
Callable warrant to purchase one share of Centocor
Common Stock (incorporated by reference to Exhibit
4.3 to Amendment No. 4 to Form S-1/S-3 Registration
Statement of Tocor II and Centocor, Reg. No. 33-
44072).
3
<PAGE>
10.1* Form of Non-Qualified Stock Option Agreement
(incorporated by reference to Exhibit 10.01 to
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1987).
10.2* Incentive Stock Option Plan, as amended (incorporated
by reference to Exhibit 10.03 to Registrant's Annual
Report on Form 10-K for the year ended December 31,
1986).
10.3* 1983 Incentive Stock Option Plan, as amended
(incorporated by reference to Exhibit 10.04 to
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1986).
10.4* 1983 Restricted Common Stock Award Plan, as amended
and restated (incorporated by reference to Exhibit
10.04 to Registrant's Annual Report on Form 10-K for
the year ended December 31, 1993).
10.5* 1987 Non-Qualified Stock Option Plan, as amended and
restated (incorporated by reference to Exhibit 10.05
to Registrant's Annual Report on Form 10-K for the
year ended December 31, 1990).
10.6* 1989 Non-Employee Directors' Non-Qualified Stock
Option Plan (incorporated by reference to Exhibit
10.06 to Registrant's Annual Report on Form 10-K for
the year ended December 31, 1989).
10.7 Lease Agreement for property located at Great Valley
Parkway, Malvern, PA 19355 (incorporated by reference
to Exhibit 10.07 to Registrant's Annual Report on
Form 10-K for the year ended December 31, 1989).
10.8 Partnership Purchase Option Agreement among Centocor,
Inc., CCIP, Centocor Development Corporation I, each
Class A limited partner and the Class B limited
partner, dated September 12, 1985 (incorporated by
reference to Exhibit 10.53 to Registrant's Post
Effective Amendment No. 1 to Form S-1 Registration
Statement, File No. 2-95057).
10.9 Indemnity Agreement between Centocor, Inc. and CCIP,
dated September 12, 1985 (incorporated by reference
to Exhibit 10.71 to Registrant's Post Effective
Amendment No. 1 to Form S-1 Registration Statement,
File No. 2-95057).
10.10* Qualified Savings and Retirement Plan, as amended and
restated (incorporated by reference to Exhibit 10.14
to Registrant's Annual Report on Form 10-K for the
year ended December 31, 1989).
10.11 Partnership Purchase Option Agreement among Centocor,
Inc., CPII, Centocor Development Corporation II, each
Class A limited partner and the Class B limited
partner, dated December 17, 1986 (incorporated by
reference to Exhibit 10.23 to Registrant's Annual
Report on Form 10-K for the year ended December 31,
1986).
4
<PAGE>
10.12 Indemnity Agreement between Centocor, Inc. and CPII,
dated December 17, 1986 (incorporated by reference to
Exhibit 10.26 to Registrant's Annual Report on Form
10-K for the year ended December 31, 1986).
10.13 Indemnity Agreement between CPIII and Centocor, Inc.,
dated December 23, 1987 (incorporated by reference to
Exhibit 10.41 to Registrant's Annual Report on Form
10-K for the year ended December 31, 1987).
10.14 Partnership Purchase Option Agreement among Centocor,
Inc., CPIII, Centocor Development Corporation III,
and the Class C limited partner, dated December 23,
1987 (incorporated by reference to Exhibit 10.43 to
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1987).
10.15 Amendment dated March 23, 1988 to Partnership
Purchase Option Agreement among Centocor, Inc.,
CPIII, Centocor Development Corporation III and the
Class C limited partner dated December 23, 1987
(incorporated by reference to Exhibit 10.37 to
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1988).
10.16 Series E, F and G Preferred Stock Purchase Agreement
dated as of November 20, 1991 between Centocor
Delaware, Inc. and Corvas International, Inc.
(incorporated by reference to Exhibit 10.28 to Form
S-1 Registration Statement of Corvas International,
Inc. Reg. No. 33-44555).
10.17 Sales and Distribution Agreement between Centocor,
Inc. and Eli Lilly and Company dated July 15, 1992.
(The Registrant has requested confidential treatment
from the Securities and Exchange Commission for
portions of this Agreement.) (incorporated by
reference to Exhibit 10.32 to Registrant's Annual
Report on Form 10-K for the year ended December 31,
1992).
10.18 Reimbursement Agreement between Centocor, Inc. and
Eli Lilly and Company dated July 15, 1992. (The
Registrant has requested confidential treatment from
the Securities and Exchange Commission for portions
of this Agreement.) (incorporated by reference to
Exhibit 10.33 to Registrant's Annual Report on Form
10-K for the year ended December 31, 1992).
10.19 Investment Agreement between Centocor, Inc. and Eli
Lilly and Company dated July 15, 1992. (The
Registrant has requested confidential treatment from
the Securities and Exchange Commission for portions
of this Agreement.) (incorporated by reference to
Exhibit 10.34 to Registrant's Annual Report on Form
10-K for the year ended December 31, 1992).
10.20 Amendment to Sales and Distribution Agreement among
Centocor, Inc., Centocor B.V. and Eli Lilly and
Company dated June 27, 1993. (The Registrant has
requested confidential treatment from the Securities
and
5
<PAGE>
Exchange Commission for portions of this Agreement.)
(incorporated by reference to Exhibit 10.35 to
Registrant's Annual Report on Form 10-K for the year
ended December 31, 1993).
10.21 Option Agreement between Centocor B.V. and Eli Lilly
Nederland B.V. dated August 20, 1993. (The Registrant
has requested confidential treatment from the
Securities and Exchange Commission for portions of
this Agreement.) (incorporated by reference to
Exhibit 10.36 to Registrant's Annual Report on Form
10-K for the year ended December 31, 1993).
10.22 Deed of Mortgage from Centocor B.V. to Eli Lilly
Nederland B.V. dated August 26, 1993 (incorporated by
reference to Exhibit 10.37 to Registrant's Annual
Report on Form 10-K for the year ended December 31,
1993).
10.23 Deed of Pledge from Centocor B.V. to Eli Lilly
Nederland B.V. dated August 26, 1993 (incorporated by
reference to Exhibit 10.38 to Registrant's Annual
Report on Form 10-K for the year ended December 31,
1993).
10.24 Amendment to Sales and Distribution Agreement among
Centocor, Inc., Centocor B. V. and Eli Lilly and
Company dated July 26, 1996. (The Registrant has
requested confidential treatment from the Securities
and Exchange Commission for portions of this
Agreement).
10.25 Stock Purchase Agreement made as of December 16, 1993
by and between Centocor, Inc. and The Wellcome
Foundation Limited (incorporated by reference to
Exhibit 10(a) to the Registrant's Current Report on
Form 8-K dated December 16, 1993).
10.26 Supply, Distribution and Sales Agreement dated
December 16, 1993 by and among Centocor, Inc.,
Centocor B.V., The Wellcome Foundation Limited and
Burroughs Wellcome Co. (The Registrant has requested
confidential treatment from the Securities and
Exchange Commission for portions of this Agreement.)
(incorporated by reference to Exhibit 10(b) to the
Registrant's Current Report on Form 8-K dated
December 16, 1993).
10.27 Clinical and Regulatory Development Agreement dated
December 16, 1993 among Centocor, Inc., Centocor
B.V., The Wellcome Foundation Limited and Burroughs
Wellcome Co. (The Registrant has requested
confidential treatment from the Securities and
Exchange Commission for portions of this Agreement.)
(incorporated by reference to Exhibit 10(c) to the
Registrant's Current Report on Form 8-K dated
December 16, 1993).
10.28 Centocor Technology License Agreement dated as of
December 16, 1993 among Centocor, Inc., Centocor
B.V., The Wellcome Foundation Limited and Burroughs
Wellcome Co. (The Registrant has requested
confidential treatment from the Securities and
Exchange Commission for portions of
6
<PAGE>
this Agreement.) (incorporated by reference to
Exhibit 10(e) to the Registrant's Current Report on
Form 8-K dated December 16, 1993).
10.29 Relicense Agreement dated as of December 16, 1993
among Centocor, Inc., Centocor B.V., The Wellcome
Foundation Limited and Burroughs Wellcome Co.
(incorporated by reference to Exhibit 10(f) to the
Registrant's Current Report on Form 8-K dated
December 16, 1993).
10.30 Appendix A - Glossary of Terms to each of the
Agreements dated as of December 16, 1993 by and among
Centocor, Inc., Centocor B.V., The Wellcome
Foundation Limited and Burroughs Wellcome Co. (The
Registrant has requested confidential treatment from
the Securities and Exchange Commission for portions
of this Agreement.) (incorporated by reference to
Exhibit 10(g) to the Registrant's Current Report on
Form 8-K dated December 16, 1993).
10.31 First Supplemental Agreement dated as of November 15,
1994 among Centocor, Inc., Centocor B.V., The
Wellcome Foundation Limited and Burroughs Wellcome
Co. (The Registrant has requested confidential
treatment from the Securities and Exchange Commission
for portions of this Agreement.) (incorporated by
reference to Exhibit 10(a) to the Registrant's
Current Report on Form 8-K dated November 15, 1994).
10.32 Wellcome Clinical Development Agreement dated as of
November 15, 1994 among Centocor, Inc., Centocor
B.V., The Wellcome Foundation Limited and Burroughs
Wellcome Co. (The Registrant has requested
confidential treatment from the Securities and
Exchange Commission for portions of this Agreement.)
(incorporated by reference to Exhibit 10(b) to the
Registrant's Current Report on Form 8-K dated
November 15, 1994).
10.33 Distribution Agreement between Centocor, Inc. and
Fujisawa Pharmaceutical Co. Ltd dated August 15,
1996. (Registrant has requested confidential
treatment from the Securities and Exchange Commission
for portions of this Agreement) (incorporated by
reference to same-numbered exhibit to Registrant's
Annual Report on Form 10-K for the year ended
December 31, 1996).
11 Computation of Earnings (Loss) per Common Share
(incorporated by reference to same-numbered exhibit
to Registrant's Annual Report on Form 10-K for the
year ended December 31, 1996).
12 Statement re: Computation of Ratios (incorporated by
reference to same-numbered exhibit to Registrant's
Annual Report on Form 10-K for the year ended
December 31, 1996).
21 Subsidiaries of the Registrant (incorporated by
reference to same-numbered exhibit to Registrant's
Annual Report on Form 10-K for the year ended
December 31, 1996).
23 Consent of Independent Auditors.
27 Financial Data Schedule (incorporated by reference to
same-numbered exhibit to Registrant's Annual Report
on Form 10-K for the year ended December 31, 1996).
*These exhibits constitute compensatory plans.
7
<PAGE>
b. The Registrant has filed the following reports on Form 8-K since the
beginning of the quarter ended December 31, 1996:
None
For the purposes of complying with the amendments to the rules
governing Form S-8 (effective July 13, 1990) under the Securities Act
of 1933, the undersigned registrant hereby undertakes as follows,
which undertaking shall be incorporated by reference into registrant's
Registration Statements on Form S-8, Nos. 2-86486, 33-16285, 33-00167,
33-35731, 33-23480, 33-16284, and 33-35730.
Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers and
controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the
opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Securities Act of 1933
and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by
the registrant of expenses incurred or paid by a director, officer or
controlling person of the registrant in the successful defense of any
action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered,
the registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such indemnification by
it is against public policy as expressed in the Act and will be
governed by the final adjudication of such issue.
8
<PAGE>
Centocor Partners III, L.P.
Balance Sheets
- -------------------------------------------------------------------------------
<TABLE>
<CAPTION>
December 31, December 31,
1996 1995
------------- -------------
<S> <C> <C>
Assets
Cash $ 32,646 $ 4,187
Investment in joint venture 3,677,478 618,011
----------- -----------
Total Assets $ 3,710,124 $ 622,198
=========== ===========
Liabilities
Current liabilities:
Accounts payable and accrued expenses $ 78,325 $ 70,133
Due to Centocor, Inc. (Note 7) 6,801,420 7,954,507
----------- -----------
6,879,745 8,024,640
Partners' capital (Note 4) (3,169,621) (7,402,442)
----------- -----------
Total Liabilities and Partners' capital $ 3,710,124 $ 622,198
=========== ===========
</TABLE>
See accompanying Notes to Financial Statements.
- -------------------------------------------------------------------------------
9
<PAGE>
Centocor Partners III, L.P.
Statements of Operations
- -------------------------------------------------------------------------------
<TABLE>
<CAPTION>
For the Years ended December 31, 1996 1995 1994
------------- -------------- --------------
<S> <C> <C> <C>
Revenues:
Equity in earnings of
joint venture (Note 6) $ 7,850,936 $ 1,269,919 $ 4,490
------------ ------------- -------------
Costs and Expenses:
Research and development (Note 7) 29,120,796 29,900,000 22,850,000
General and administrative 131,794 23,548 4,500
------------ ------------ ------------
29,252,590 29,923,548 22,854,500
------------ ------------ ------------
Loss for the period $(21,401,654) $(28,653,629) $(22,850,010)
============ ============ ============
</TABLE>
See accompanying Notes to Financial Statements.
- --------------------------------------------------------------------------------
10
<PAGE>
Centocor Partners III, L.P.
Statements of Cash Flows
- --------------------------------------------------------------------------------
<TABLE>
<CAPTION>
For the Years ended December 31, 1996 1995 1994
------------ ------------ ------------
<S> <C> <C> <C>
Cash flows used for operating activities:
Loss $(21,401,654) $(28,653,629) $(22,850,010)
Change in due to Centocor, Inc. (1,153,087) 957,381 2,863,000
Change in accounts payable
and accrued expenses 8,192 27,726 4,500
Change in investment in joint venture (3,059,467) (106,381) (4,490)
------------ ------------ ------------
Net cash used for operating activities (25,606,016) (27,774,903) (19,987,000)
Cash flows from financing activities:
Distributions to partners (4,653,278) (1,163,538) -
General partner capital contributions 30,287,753 28,942,628 19,987,000
------------ ------------ ------------
Net cash from financing activities 25,634,475 27,779,090 19,987,000
------------ ------------ ------------
Increase in cash and cash equivalents 28,459 4,187 -
Cash and cash equivalents at beginning of year 4,187 - -
------------ ------------ ------------
Cash and cash equivalents at end of year $ 32,646 $ 4,187 $ -
============ ============ ============
</TABLE>
See accompanying Notes to Financial Statements.
- -------------------------------------------------------------------------------
11
<PAGE>
Centocor Partners III, L.P.
Statements of Partners' Capital
- -------------------------------------------------------------------------------
<TABLE>
<CAPTION>
Limited General
Partners Partner Total
------------ ---------- -------------
<S> <C> <C> <C>
Balance, December 31, 1993 $ 470,452 $ (4,135,345) $ (3,664,893)
Contributions - 19,987,000 19,987,000
Loss (10) (22,850,000) (22,850,010)
------------ ------------- -------------
Balance, December 31, 1994 470,442 (6,998,345) (6,527,903)
Distributions (1,151,903) (11,635) (1,163,538)
Contributions - 28,942,628 28,942,628
Income (Loss) 1,233,530 (29,887,159) (28,653,629)
------------ ------------- -------------
Balance, December 31, 1995 552,069 (7,954,511) (7,402,442)
Distributions (4,606,745) (46,533) (4,653,278)
Contributions - 30,287,753 30,287,753
Income (Loss) 7,631,925 (29,033,579) (21,401,654)
------------ ------------- -------------
Balance, December 31, 1996 $ 3,577,249 $ (6,746,870) $ (3,169,621)
============ ============= =============
</TABLE>
See accompanying Notes to Financial Statements.
- -------------------------------------------------------------------------------
12
<PAGE>
Centocor Partners III, L.P.
Notes to Financial Statements
- --------------------------------------------------------------------------------
1. Basis of Presentation
---------------------
Centocor Partners III, L.P. ("CPIII" or the "Partnership"), was formed in
December 1987, and is managed by its general partner, Centocor Development
Corporation III, a wholly owned subsidiary of Centocor, Inc. ("Centocor"), a
Pennsylvania corporation, which is subject to the reporting requirements of the
Securities Exchange Act of 1934. The Partnership was organized to develop and
derive income from the sale of one therapeutic product (ReoPro) and one imaging
product (Capiscint) which are expected to be used in the treatment and
diagnosis, respectively, of two different types of cardiovascular disease.
In 1987 and 1988, the Partnership and Centocor sold (a) 542.25 units,
consisting of 111 Class C limited partnership interests and 431.25 Class A
limited partnership interests each together with warrants to purchase shares of
Centocor common stock, and (b) one Class B limited partnership interest,
together with warrants to purchase shares of Centocor common stock. The
purchase prices were $90,000 for the Class C interests, $100,000 for the Class A
interests and $150,000 for the Class B interest.
The net proceeds from the sale of limited partnership interests were used
primarily to pay expenses incurred under the Partnership's agreement with
Centocor (the "Development Agreement") to perform research and development for
the Partnership (see Note 7).
The Partnership also entered into a Cross License Agreement pursuant to
which Centocor granted to the Partnership an exclusive license to use all patent
rights, know-how, technical information and biological materials owned or
controlled by Centocor within the Partnership's field of activity. Under the
Cross License Agreement, the Partnership agreed to grant to Centocor an
exclusive royalty-free license to all patent rights, know-how, technical
information and biological materials arising from research and development
conducted under the Development Agreement for all purposes outside of the
Partnership's field of activity.
Centocor entered into a Partnership Purchase Option Agreement with each of
the limited partners. On January 31, 1997, Centocor exercised its option to
acquire the Class A and Class C limited partnership interests. In connection
therewith, the general partner has terminated the research program and after the
acquisition of the Class B limited partnership interests, which is expected to
occur on or about May 1, 1997, the partnership is expected to dissolve. (See
Note 5)
2. Summary of Significant Accounting Policies
------------------------------------------
Investment in Joint Venture
---------------------------
The Partnership accounts for its investment in the joint venture (see Note
6) under the equity method of accounting. The joint venture is expected to
terminate in 1997 upon the occurrence of certain events. (See Note 5)
13
<PAGE>
Centocor Partners III, L.P.
Notes to Financial Statements
- --------------------------------------------------------------------------------
Income Taxes
------------
The Partnership's distributable income or loss is reportable for income tax
purposes by the partners; therefore, no provision for income taxes has been made
in the accompanying financial statements. The Partnership's tax returns are
subject to examination by federal and state taxing authorities. Because many
types of transactions are susceptible to varying interpretations under federal
and state income tax laws and regulations, certain amounts may be subject to
change at a later date upon final determination by the respective taxing
authorities.
3. Contingencies
-------------
In July 1995, PaineWebber Development Corporation ("PaineWebber"), a
wholly-owned subsidiary of PaineWebber Group, Inc., caused suit to be filed
against Centocor and Centocor Development Corporation III ("CDCIII", the general
partner of the Partnership and a wholly-owned subsidiary of Centocor) by a
development partnership formed in the mid 1980s by PaineWebber and managed by it
since then. The PaineWebber partnership, PaineWebber R&D Partners II,
L.P.("PWR&DII"), an investor in the Partnership, filed suit in the Court of
Chancery of the State of Delaware. In the complaint, the plaintiff seeks to sue
derivatively on behalf of CPIII. The Partnership is named as a nominal defendant
and Centocor and CDCIII are named as defendants against whom relief is sought.
The claim is that at least $25 million of the money paid by Eli Lilly and
Company ("Lilly") to Centocor in 1992 represented profits from the marketing of
ReoPro, obligating Centocor to pay a portion thereof to the Partnership, and
that Centocor is obligated to pay an increased percentage of the profits from
ReoPro to the Partnership going forward. Centocor answered the complaint in the
Delaware action and filed a cross-claim against nominal defendant CPIII and a
third party complaint against PaineWebber Group Inc. and PaineWebber Development
Corporation. The cross-claim seeks an offset against any damages awarded the
partners based on theories of unjust enrichment and quasi contract. The third-
party claims (since amended to add additional theories of liability and to make
PaineWebber, Inc. an additional third-party defendant) seek to hold the
PaineWebber entities liable for some or all of any alleged injury to the
partnership. On November 1, 1995, an additional suit was commenced in the
Delaware Court of Chancery by a limited partner, John E. Abdo, against Centocor
and CDCIII and certain of their officers and directors. The complaint, filed
derivatively on behalf of the Partnership, asserts claims, inter alia, for
breach of contract, breach of fiduciary duty, common law fraud, and conspiracy
and aiding and abetting. Centocor answered this complaint and also filed a
cross-claim against nominal defendant CPIII and a third-party complaint against
PaineWebber Group, Inc., and PaineWebber, since amended to add additional
theories of liability and to name PaineWebber, Inc. as a further third-party
defendant. Abdo moved to amend his complaint to assert claims against the
persons appointed by PaineWebber to the CDCIII Board of Directors. That motion
was granted. Motions to disqualify PWR&DII from serving as the derivative
plaintiff were filed in July 1996 by CPIII and in August 1996 by Centocor and
CDCIII. Abdo joined those motions. No decision has been issued on those motions.
The parties in the PWR&DII suit have considered ways and means to resolve the
issues without further litigation. The Partnership incurred approximately
$131,794 in legal expenses related to these suits in 1996 and cumulative legal
expenses to date of approximately $155,000 as a result of being named a nominal
defendant in the above suits.
Under paragraph 7.8 of the Agreement of Limited Partnership, the
Partnership is obligated, under certain conditions, to indemnify CDCIII and its
officers and directors in respect of all fees,
14
<PAGE>
Centocor Partners III, L.P.
Notes to Financial Statements
- --------------------------------------------------------------------------------
costs and expenses incurred in connection with or resulting from any claim
against CDCIII and its officers and directors that arises out of or in any way
relates to the Partnership or its properties, business or affairs including any
losses or damages resulting from such claims and amounts paid in settlement or
compromise. Therefore, the Partnership may incur legal expenses and other costs
pertaining to the suits described above.
CPIII is expected to terminate in 1997 pursuant to the purchase by Centocor
of all limited partner interests. (See Note 5)
4. Partners' Capital
-----------------
Profits and losses of the Partnership are generally allocated 1 percent to
the general partner and 99 percent to the limited partners. Losses resulting
from research and development expenditures in excess of the limited partners'
capital contributions are allocated to the general partner (see Note 7).
5. Partnership Purchase Option
---------------------------
On January 31, 1997, Centocor exercised its purchase option and made an
advance payment to the Class A and Class C limited partners of $13,598,000 in
the aggregate. Centocor plans to exercise its option to purchase the Class B
limited Partnership interest by making a payment of $41,500 in the aggregate on
or about May 1, 1997 at which time the joint venture will terminate.
CPIII is expected to terminate on or around July 30, 1997 pursuant to the
transfer of all limited partner interests to Centocor. Pursuant to the terms of
the Partnership Purchase Agreement, Centocor will make future quarterly royalty
payments to the former limited partners. For each quarter beginning with the
first quarter of the year 2000, Centocor's payments to the former limited
partners will be reduced by 25 percent of the amount otherwise payable to the
former limited partners until Centocor has recouped the amount of the advance
payment.
6. Joint Venture
-------------
The Partnership and Centocor formed a joint venture for the purpose of
commercializing any products developed within the Partnership's field of
activity. The Joint Venture Agreement provided that Centocor manufacture the
products on behalf of the joint venture for its actual costs of manufacturing.
Under the Joint Venture Agreement, Centocor also provided marketing services for
the joint venture for a commission of 17 percent of joint venture sales and
received 10 percent of joint venture sales as reimbursement for its management
and administrative services. The profits and losses of the joint venture are to
be allocated approximately 75 percent to Centocor and 25 percent to the
Partnership.
The joint venture will terminate upon Centocor's exercise of the option to
purchase the Class B limited Partnership interest.
In July 1992, Centocor and Lilly entered into a Sales and Distribution
Agreement later amended in June 1993. Under that Agreement, as amended in June
1993, Centocor is principally responsible for developing and manufacturing
ReoPro, and Lilly will assist Centocor in the
15
<PAGE>
Centocor Partners III, L.P.
Notes to Financial Statements
- --------------------------------------------------------------------------------
regulatory filings and continued development of ReoPro for various clinical
indications. Also, in the event Centocor cannot manufacture ReoPro or under
certain other circumstances, such as material breach of the agreement by or the
bankruptcy of Centocor, Lilly has the option to assume the manufacture of ReoPro
and assure the continued supply of the product, even to the extent of acquiring
Centocor's related manufacturing assets at their independently appraised values.
In June 1996, Centocor and Lilly amended the Sales and Distribution
Agreement. Under this amendment, Lilly no longer has the right to buy ReoPro for
resale in Japan; however, Lilly will maintain its exclusive right to buy and
resell ReoPro in the rest of the world.
In August 1996, Centocor entered into an agreement with Fujisawa
Pharmaceutical Co., Ltd., appointing Fujisawa as the exclusive distributor of
ReoPro in Japan. Centocor and Fujisawa will co-develop ReoPro in Japan and
jointly file for Japanese product approval. Fujisawa shall bear all external
costs associated with the clinical development of ReoPro in Japan.
Through the joint venture, Centocor commenced sales of ReoPro to Lilly in
January 1995. ReoPro sales to Lilly for the twelve months ended December 31,
1996 were $88,669,000. The level of sales of ReoPro will depend upon a number
of factors, including the timing and extent of additional regulatory approvals
for ReoPro, approval and commercialization of competitive products, the degree
of acceptance of ReoPro in the marketplace, and the strength of Centocor's
patent position and that of others.
7. Research Funding
----------------
The initial funding by the limited partners for the Partnership's research
program pursuant to the Development Agreement with Centocor was exhausted in
1990. In order to continue the research program, the Partnership extended the
terms of the Development Agreement with Centocor. Approximately $143,383,000 of
the Partnership's research costs through December 31, 1996 were funded by the
general partner. At December 31, 1996 and 1995, approximately $6,801,000 and
$7,955,000, respectively, were due to Centocor for expenditures under the
Development Agreement. Pursuant to Centocor's purchase of the Class A and Class
C limited partner interests as per Note 5, the General Partner has terminated
the research program in accordance with the Development Agreement.
16
<PAGE>
INDEPENDENT AUDITORS' REPORT
The Partners of Centocor Partners III, L.P.:
We have audited the accompanying balance sheets of Centocor Partners III, L.P.
("the Partnership") as of December 31, 1996 and 1995, and the related statements
of operations, cash flows and partners' capital for each of the years in the
three-year period ended December 31, 1996. These financial statements are the
responsibility of the Partnership's management. Our responsibility is to
express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
As disclosed in Notes 1 and 5 to the financial statements, on January 31, 1997,
Centocor exercised its option to acquire the Class A and Class C limited
Partnership interests. In connection therewith, the general partner has
terminated the research program and after the acquisition of the Class B limited
Partnership interests, which is expected to occur on or about May 1, 1997, the
Partnership is expected to dissolve.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Centocor Partners III, L.P. at
December 31, 1996 and 1995, and the results of its operations and its cash flows
for each of the years in the three-year period ended December 31, 1996, in
conformity with generally accepted accounting principles.
KPMG Peat Marwick LLP
Philadelphia, Pennsylvania
January 31, 1997
17
<PAGE>
Schedule II
CENTOCOR, INC. AND SUBSIDIARIES
VALUATION AND QUALIFYING ACCOUNTS
FOR THE THREE YEARS ENDED DECEMBER 31, 1996
(IN THOUSANDS)
<TABLE>
<CAPTION>
Balance Charged to Balance Charged to Balance Charged to Balance
at Costs and at Costs and at Costs and at
Classification 12/31/93 Expenses Deductions 12/31/94 Expenses Deductions 12/31/95 Expenses Deductions 12/31/96
- -------------- -------- --------- ---------- -------- ---------- ---------- -------- ---------- ---------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Inventory Reserves $64,743 $3,609 ($53,472) $14,880 $2,094 ($15,938) $1,036 $662 ($357) $1,341
================================================================================================================
</TABLE>
18
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this Form 10-K/A report to
be signed on its behalf by the undersigned, thereunto duly authorized.
CENTOCOR, INC.
Date: May 13, 1998 By: /s/ Dominic J. Caruso
-----------------------------------
Dominic J. Caruso
Senior Vice President - Finance and
Chief Financial Officer
19
<PAGE>
EXHIBIT INDEX
Exhibit Number
--------------
10.24 Amendment to Sales and Distribution Agreement among
Centocor, Inc., Centocor B.V. and Eli Lilly and
Company dated June 26, 1996. (The Registrant has
requested confidential treatment from the Securities
and Exchange Commission for portions of this
Agreement.)
23 Consent of Independent Auditors.
<PAGE>
CONFIDENTIAL TREATMENT
EXHIBIT 10.24
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN PORTIONS OF THIS
AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF THE AGREEMENT AT
THE PLACES INDICATED BY "XXXXXXXXXX"; AND HAVE BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.
AMENDMENT TO SALES AND DISTRIBUTION AGREEMENT
---------------------------------------------
AMENDMENT TO SALES AND DISTRIBUTION AGREEMENT ("Amendment") made as of June
26, 1996, by and among CENTOCOR, INC. a Pennsylvania corporation ("CNTO"),
CENTOCOR B.V., a Netherlands corporation ("CBV"); and together with CNTO,
collectively, ("Centocor"), and ELI LILLY AND COMPANY, an Indiana corporation
("Lilly").
BACKGROUND
----------
A. Centocor and Lilly are parties to a certain Sales and Distribution
Agreement dated July 15, 1992, as amended (the "Agreement").
B. Centocor and Lilly now desire to amend certain provisions of the
Agreement as set forth herein.
C. Capitalized terms used but not defined herein shall have the meanings
given to them in the Agreement.
NOW, THEREFORE, Centocor and Lilly, each intending to be legally bound
hereby, agree as follows:
1. Amendments. The Agreement shall be amended as follows:
1.1 ReoPro. All references in the Agreement to "CentoRx" shall be
deemed to refer to "ReoPro", and Section 1.6 of the Agreement shall be amended
and restated in its entirety to read as follows:
"l.6 "ReoPro" means the 7E3(TM) monoclonal antibody pharma-
ceutical product known as ReoPro(R) in the Territory."
1.2 Territory. Notwithstanding any provision of the Agreement to the
contrary, including, without limitation, Section 13.4 of the Agreement, the term
"Territory" as it applies to ReoPro shall mean "the entire world, except for
Japan".
2. Continuing Research, Development and Commercialization of ReoPro.
Notwithstanding anything in the Agreement, or any correspondence or discussions
entered into in connection therewith, Centocor and Lilly hereby agree that all
costs and expenses as described in Article VII and Exhibit A of the Agreement
incurred after the date of this Amendment in connection with the continued
research, development and commercialization of ReoPro in the Territory,
including, but not limited to, costs and expenses of clinical studies for
XXXXXXXXXX shall be shared XXXXXXXXXX by Centocor and Lilly in accordance with
the XXXXXXXXXX sharing
<PAGE>
system described in Article VII and Exhibit A of the Agreement. Notwithstanding
the foregoing, all cost sharing as described in this Amendment and the Agreement
shall be limited to those costs related to plans approved by the Product
Committee.
3. Clinical Development of ReoPro. Centocor and Lilly each hereby agree
to proceed with the clinical development of ReoPro for XXXXXXXXXX.
4. Closing Date; Settlement Date. The closing of the transactions
contemplated by this Amendment is to be held on June 26, 1996 (the "Closing
Date"). The transactions contemplated by this Amendment including, but not
limited to, the amendments set forth in Section 1 hereof shall only become
effective on the Closing Date provided that all the conditions set forth in
Section 10 hereof are fully satisfied or waived as described in Section 10 of
this Amendment. On July 9, 1996 (the "Settlement Date") CNTO shall deliver to
Lilly a certificate or certificates representing the Shares to be issued to
Lilly pursuant to the provisions of Section 5 of this Amendment.
5. Consideration.
5.1 Consideration for Amendment. In consideration of Lilly's
agreement to amend the Agreement to exclude Japan from the Territory as provided
in Section 1.2 hereof and Lilly's agreement as set forth in Section 13 hereof,
on the Settlement Date, CNTO shall issue to Lilly such number of shares
("Amendment Shares") of CNTO's common stock, par value $ .01 per share ("Common
Stock"), as determined by dividing XXXXXXXXXX by the average of the last
reported sale price per share of CNTO Common Stock on the NASDAQ National Market
for the five (5) Trading Days (hereinafter defined as in Section 5.3 hereof)
immediately preceding the Settlement Date (the "Average Price").
5.2 Other Consideration. In consideration of XXXXXXXXXX, which the
parties acknowledge will strengthen scientific and marketing support for ReoPro,
and in consideration of Lilly's agreements with respect to the development
XXXXXXXXXX as described in Section 2 and 3 above, on the Settlement Date, CNTO
shall issue to Lilly such number of shares ("Other Shares"; and together with
the Amendment Shares, the "Shares") of CNTO's Common Stock, as determined by
dividing XXXXXXXXXX by the Average Price.
5.3 Post-Closing Adjustment.
(a) If the Registration Statement (as defined in Section 7.1
hereof) is declared effective by the Securities and Exchange Commission ("SEC")
within the five (5) Trading Days (as hereinafter defined) immediately following
the Settlement Date, no post-closing adjustment shall be made to the
consideration set forth in Section 5.1 and 5.2 hereof. For the purposes of this
Amendment, a "Trading Day" shall mean a day on which the NASDAQ National Market
is open
-2-
<PAGE>
for business. The date on which the Registration Statement is declared
effective is referred to herein as the "Registration Date".
(b) If the Registration Statement is not declared effective by
the SEC within the five (5) Trading Days immediately following the Settlement
Date, a post-closing adjustment shall be calculated as follows:
(i) if the product of X, the average of the last reported
sale price per share of CNTO Common Stock on the NASDAQ National Market for the
five Trading Days immediately preceding the Registration Date (the "Registration
Date Closing Price"), multiplied by Y, the total number of Shares or Shortfall
Shares, whichever may be the case, issued to Lilly under this Amendment, is less
than $27,000,000, then CNTO shall pay the difference (the "Shortfall Amount") to
Lilly within five (5) business days following the Registration Date. CNTO shall
have the option of paying the Shortfall Amount in cash or in shares of CNTO
Common Stock; or
(ii) if the product of X, the Registration Date Closing
Price, multiplied by Y, the total number of Shares issued to Lilly under this
Agreement, is greater than $27,000,000, then Lilly shall pay the difference (the
"Excess Amount"). Lilly shall pay the Excess Amount to CNTO within five (5)
business days following the Registration Date. Lilly shall have the option of
paying the Excess Amount in cash or in shares of CNTO Common Stock.
(c) If CNTO is obligated to pay the Shortfall Amount and elects
to make such payment in shares of CNTO Common Stock: (i) the number of shares
(the "Shortfall Shares") of CNTO Common Stock to be delivered to Lilly shall be
determined by dividing the Shortfall Amount by the Registration Date Closing
Price; and (ii) the provisions of this Section 5.3 and Sections 5.4, 6, 7 and 11
of this Amendment shall apply to the Shortfall Shares as if they were "Shares"
as such term is used in those Sections; provided, however, that with respect to
the Shortfall Shares, references to the Settlement Date shall mean the date the
Shortfall Shares are delivered by CNTO to Lilly and references to the
$27,000,000 shall mean the Shortfall Amount.
(d) If Lilly is obligated to pay the Excess Amount and elects to
make such payment in shares of CNTO Common Stock the number of shares of CNTO
Common Stock to be delivered to CNTO shall be determined by dividing the Excess
Amount by the Registration Date Closing Price.
5.4 Late Fee Penalty. In the event that the Registration Date does
not occur within five (5) Trading Days immediately following the Settlement
Date, a daily late fee penalty shall be imposed on CNTO for each day after the
Settlement Date through the day immediately prior to the Registration Date (the
"Late Fee"). The daily Late Fee imposed shall be equal to the United States
three-month Treasury Bill interest rate, divided by 365 days, as quoted in the
Wall Street Journal as of the Settlement Date, multiplied by Seventeen Million
Dollars ($17,000,000). The Late Fees shall be due and payable to Lilly thirty
(30) days after the Settlement Date and to the extent applicable every thirty
(30) days thereafter.
-3-
<PAGE>
6. Restriction of Transferability
6.1 Transfers Generally. The Shares shall be transferable only upon
the conditions specified in this Section 6, which conditions are intended to
insure compliance with the provisions of the Securities Act of 1933, as amended,
and the Regulations promulgated thereunder or with respect thereto, or any
successor or substitute laws (the "1933 Act").
6.2 Transfers of Shares Pursuant to Registration Statements and Rule
144. The Shares may be offered or sold by Lilly pursuant to (a) an effective
registration statement under the 1933 Act, or (b) to the extent applicable, Rule
144 ("Rule 144") as promulgated by the Securities and Exchange Commission
("SEC") under the 1933 Act.
6.3 Other Transfers. Lilly may transfer any or all of the Shares,
without registration or without compliance with the provisions of Rule 144, so
long as it so notifies CNTO and such notification is accompanied by an opinion
of counsel reasonably acceptable to CNTO to the effect that such transfer may be
made without registration under the 1933 Act of the Shares sought to be
transferred.
6.4. Restrictive Legends. Until otherwise permitted by Section 6.5
hereof, each certificate representing any of the Shares shall bear a legend in
substantially the following form:
THE SALE, DISPOSITION OR OTHER TRANSFER OF THE SECURITIES REPRESENTED
BY THIS CERTIFICATE IS SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFERS
SPECIFIED IN THAT CERTAIN AMENDMENT TO SALES AND DISTRIBUTION AGREEMENT
DATED AS OF JUNE 26, 1996, BETWEEN CENTOCOR, INC., CENTOCOR B.V. AND ELI
LILLY AND COMPANY, AS THE SAME MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO
TIME, AND NO TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE
SHALL BE VALID OR EFFECTIVE UNTIL THE CONDITIONS TO ANY TRANSFER WHICH ARE
SET FORTH IN SUCH AGREEMENT HAVE BEEN SATISFIED. A COPY OF THE FORM OF
SUCH AGREEMENT IS ON FILE AT THE OFFICE OF THE SECRETARY OF CENTOCOR, INC.
AND MAY BE INSPECTED DURING NORMAL BUSINESS HOURS.
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, NOR HAVE ANY OF
THEM BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES OR BLUE SKY LAWS OF
ANY STATE. THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD,
ASSIGNED, PLEDGED, HYPOTHECATED, ENCUMBERED OR IN ANY OTHER MANNER
TRANSFERRED OR DISPOSED OF, EXCEPT IN COMPLIANCE WITH THE SECURITIES ACT OF
1933, AS AMENDED, THE RULES AND REGULATIONS
-4-
<PAGE>
PROMULGATED THEREUNDER, AND APPLICABLE STATE SECURITIES OR BLUE SKY LAWS
AND REGULATIONS.
6.5 Termination of Restrictions. All restrictions imposed on the
Shares pursuant to this Section 6 shall cease and terminate automatically as to
any particular Shares when such Shares (a) shall have been effectively
registered under the 1933 Act (whether pursuant to the provisions of Section 7
hereof, or otherwise) and applicable state securities or blue sky laws, (b)
shall have been sold under and pursuant to Rule 144, or (c) shall be eligible to
be sold under and pursuant to subsection (k) of Rule 144.
7. S-3 Registration Rights.
7.1 Registration Rights. CNTO will, at its sole expense, within
five (5) days following the Settlement Date, file a registration statement (the
"Registration Statement") with respect to the Shares on Form S-3 under the 1933
Act in a manner that will, upon being declared effective, constitute a "shelf"
registration for purposes of Rule 415 under the 1933 Act, pursuant to which
Lilly may sell the Shares, from time to time and in such amounts as Lilly may
hereafter determine in its discretion, all in a manner consistent with the
applicable provisions of the 1933 Act, and the Exchange Act of 1934, as amended,
and the Regulations promulgated thereunder or with respect thereto, or any
successor or substitute laws (the "1934 Act"). CNTO will, at its sole expense,
promptly register or qualify the Shares under such other securities or blue sky
laws of such jurisdictions within the United States as Lilly may reasonably
request and do any and all other acts and things which may be necessary or
desirable to enable Lilly to consummate the public sale or other disposition in
such jurisdictions of the Shares.
7.2 Other Filings. With respect to registration under Section 7.1,
until the second anniversary of the Settlement Date, CNTO shall prepare and file
such amendments, post effective amendments and periodic reports under the 1934
Act as may be necessary (a) to keep the Registration Statement continuously
effective, and (b) to ensure that the Registration Statement, including all
documents incorporated into the Registration Statement, does not contain any
untrue statement of a material fact or omission of a material fact necessary to
make the statements made therein not misleading. Notwithstanding the foregoing,
CNTO shall not be required to update, pursuant to this Section 7.2, any document
during a period when CNTO shall, in good faith and using reasonable business
judgment, believe that the premature disclosure of any event or information
would have a material adverse effect on, or not to be in the best interests of
CNTO and that such disclosure is not then required under the 1934 Act. In such
case, CNTO shall notify Lilly immediately that it has reached such a judgment,
without disclosing to Lilly the underlying event or information. Lilly hereby
agrees, that upon receipt of such notice from CNTO, Lilly shall forthwith
discontinue any disposition of the Shares until Lilly's receipt of the copies of
the supplemented or amended prospectus, and, if so directed by CNTO, Lilly shall
deliver to CNTO all copies in its possession, other than permanent file copies
then in Lilly's possession, of the prospectus covering such Shares current at
the time of receipt
-5-
<PAGE>
of such notice. Notwithstanding anything to the contrary in this Amendment,
CNTO shall use its commercially reasonable efforts to provide Lilly with copies
of the supplemented or amended prospectus or any other related updated document
pertaining to such event or information described in this Section 7.2 as soon as
reasonably practicable and in any event not later than thirty (30) days after
Lilly receives notice from CNTO as described in this Section 7.2.
7.3 Further Actions by Lilly. Lilly agrees to furnish to CNTO, in
writing, such information with respect to itself and the proposed distribution
by it, and to execute such documents regarding the Shares received by it
hereunder, and the intended method of disposition thereof as CNTO shall
reasonably request and as shall be required in connection with the actions to be
taken by CNTO under the provisions of this Section 7.
8. Representations and Warranties of Centocor. CNTO and CBV each
represent and warrant as follows:
8.1 Organization and Good Standing. Each of CNTO and CBV is a
corporation duly organized, validly existing and in good standing under the laws
of its jurisdiction of incorporation, is duly qualified to do business as a
foreign corporation and is in good standing in each jurisdiction in which the
nature of its business or the ownership of its property makes such qualification
necessary, except where the failure to so qualify or be in good standing would
not have a Material Adverse Effect (as defined in Section 8.8), and is
authorized to own or lease its properties and to carry on its business as it is
now being conducted. The copies of CNTO's Articles of Incorporation, as amended
and restated, and Bylaws, in the forms attached hereto as Exhibit A, are
complete and correct.
8.2 Corporate Power and Authority: Enforceability. CNTO and CBV each
have the requisite power and authority (corporate and otherwise) to execute,
deliver and perform this Amendment and to consummate the transactions
contemplated hereby. The execution, delivery and performance by CNTO and CBV of
this Amendment and the consummation by CNTO and CBV of the transactions
contemplated hereby, have been duly authorized by all necessary action
(corporate or otherwise) on its part. This Amendment constitutes a legal, valid
and binding obligation of CNTO and CBV, enforceable in accordance with its
terms.
8.3. Validity of Contemplated Transactions. The execution, delivery
and performance by CNTO and CBV of this Amendment, and the consummation by them
of the transactions contemplated hereby, do not, and will not (a) violate or
contravene any provision of CNTO's or CBV's charter or bylaws; (b) violate,
breach, conflict with, constitute under, cause the acceleration of any payments
pursuant to, or otherwise impair the good standing, validity, or effectiveness
of, any agreement, contracts, indenture, lease, license, or mortgage to which
CNTO or CBV is a party, or by which CNTO or CBV or any of CNTO's or CBV's
properties or assets are bound; or (c) violate any provision of any law, permit
or court order applicable to CNTO or CBV.
-6-
<PAGE>
8.4 Litigation, Judgments, Orders, Etc. Except as otherwise
disclosed herein, in any Schedule or Exhibit hereto, or set forth in Schedule
8.4 hereto, no suit, action, proceeding or investigation is pending or, to the
knowledge of CNTO or CBV, threatened against CNTO or CBV or any of its
subsidiaries or affiliates, which, if determined adversely to such parties,
would (i) prohibit the execution or delivery of this Amendment or the ability of
CNTO or CBV to consummate the transactions contemplated hereby, (ii) prohibit
the issuance and sale of the Shares pursuant to this Amendment, or (iii) have a
Material Adverse Effect. Except as set forth in Schedule 8.4 hereto, CNTO or
CBV is not the subject of or bound by or otherwise affected by any outstanding
judgments or decrees of any court or governmental agency that would have a
Material Adverse Effect.
8.5 Capitalization; Ownership of CBV. CNTO's total authorized
capital stock consists of 100,000,000 shares of Common Stock, of which
67,692,301 shares were issued and outstanding on May 31, 1996, all of which have
been validly issued, and are fully paid and non-assessable, and 10,000,000
shares of Preferred Stock, none of which shares are presently issued. Since May
31, 1996, CNTO has not issued any shares of Common Stock other than shares of
Common Stock issued pursuant to existing Derivative Securities (as defined
below), as set forth on Schedule 8.5 hereto. Except for such existing
Derivative Securities, CNTO does not have outstanding any Derivative Securities
or any commitments to issue any Derivative Securities. For the purposes of this
Amendment, the term "Derivative Securities" shall have the meaning ascribed to
in under Rule 16a-1(c) as promulgated by the SEC under the 1934 Act. CBV is a
direct, wholly-owned subsidiary of CNTO.
8.6 Issuance of the Shares. The Shares, when issued and delivered to
Lilly pursuant to and in accordance with the terms of this Amendment, (a) will
have been validly issued, fully paid and non-assessable, (b) will be free and
clear of any liens, (c) will have been issued without violation of any
preemptive or other right to purchase Common Stock, and (d) based in part on
representations of Lilly in this Amendment, will have been issued in compliance
with all applicable federal and state securities laws.
8.7 Other Securities and Financial Statement Matters. CNTO has duly
filed in a timely manner (without any permitted extension) all reports required
to be filed by CNTO with the SEC under the 1934 Act (the "SEC Reports"). The SEC
Reports (including, in each case, without limiting the generality thereof, the
audited and unaudited financial statements of CNTO included therein) when filed
contained all statements required to be stated therein in accordance with the
1934 Act and did not contain any untrue statement of material fact or omit to
state a material fact necessary to make any of the statements contained therein
not misleading in light of the circumstances under which they were made and
otherwise complied in all material respects with the applicable requirements of
the 1934 Act. The consolidated financial statements included in the SEC Reports
comply as to form with the requirements of Regulation S-X, as promulgated by the
SEC under the 1933 Act and are derived from the applicable books and records of
CNTO, have been prepared in conformity with generally accepted accounting
principles (as required by Regulation S-X) and present fairly the financial
-7-
<PAGE>
condition, results of operations, changes in security holders' equity and cash
flows of CNTO on a consolidated basis, as at the close of business, or for the
period ended, on the date of each of such financial statements.
8.8 Absence of Certain Changes or Events. Except as disclosed in the
financial statements referred to in Section 8.7 and CNTO's Annual Report on Form
10-K for the year ended December 31, 1995 and CNTO's Quarterly Report on Form
10-Q for the quarter ended March 31, 1996, or as otherwise disclosed herein, in
any Schedule or Exhibit hereto or listed on Schedule 8.8 hereto, since March 31,
1996, neither CNTO nor any of its subsidiaries or affiliates has incurred any
liabilities or obligations, direct or contingent, or entered into any
transactions, not in the ordinary course of business, that are material to CNTO
and its subsidiaries and affiliates, taken as a whole, and there has not been
(i) any material change in the capital stock or indebtedness of CNTO or its
subsidiaries or affiliates that would have a Material Adverse Effect (as defined
below), or (ii) any event, change or occurrence which individually or in the
aggregate might (x) have a material adverse effect on the condition (financial
or other), assets, business, or results of operations of CNTO and its
subsidiaries and affiliates, taken as a whole, (y) materially adversely affect
CNTO's ability to consummate any of the transactions contemplated hereby or to
perform its obligations under this Amendment or the Agreement or (z) materially
adversely affect CNTO's or any of its subsidiaries' or affiliates' rights in or
to the HA-lA (TM) human monoclonal antibody pharmaceutical product known as
"Centoxin(R)" or the 7E3 (TM) monoclonal antibody pharmaceutical product known
as "ReoPro(R)" (each of (x), (y) and (z) being referred to herein, individually
or in the aggregate as a "Material Adverse Effect"). Except for Derivative
Securities defined in Section 8.5 above, CNTO has not issued, or agreed to
issue, any securities or other instruments convertible into, exchangeable for or
exercisable into CNTO securities that would have a Material Adverse Effect. No
event has occurred since March 31, 1996, with respect to which CNTO would be
required to file a Current Report on Form 8-K under the 1934 Act.
8.9 Governmental Consents. Except for the filing of the Registration
Statement, no consent, approval, order or authorization of, or registration,
qualification, designation, declaration or filing with, any federal, state or
local governmental authority in the United States on the part of CNTO and CBV is
required in connection with the consummation of the transactions contemplated by
this Amendment.
8.10 Absence of Undisclosed Liabilities. Except as disclosed in the
financial statements referred to in Section 8.7, CNTO's Annual Report on Form
10-K for the year ended December 31, 1995 and CNTO's Quarterly Report on Form
10-Q for the quarter ended March 31, 1996 and as set forth in Schedule 8.10
hereto, there are no debts, liabilities or obligations, contingent or
otherwise, of CNTO or its subsidiaries or affiliates that would have a Material
Adverse Effect.
8.11 Completeness of Disclosure. Neither this Amendment, any
statements made by officers of CNTO or CBV nor any instruments or certificates
made or delivered by CNTO or CBV in connection herewith contains any untrue
-8-
<PAGE>
statement of a material fact or omits to state a material fact necessary to make
the statements made herein or therein, in light of the circumstances under which
they were made, not misleading and the other documents delivered in connection
herewith, taken as a whole, together with such statements, instruments or
certificates do not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made herein or therein,
in light of the circumstances under which they were made, not misleading.
8.12 Use of Form S-3. CNTO currently meets the conditions necessary
for use of a registration statement on Form S-3 under the 1933 Act.
8.13 Brokers and Finders. CNTO has not employed any broker, finder,
consultant or intermediary in connection with the transactions contemplated by
this Amendment who would be entitled to a broker's, finder's or similar fee or
commission in connection therewith or upon the consummation thereof.
9. Representations and Warranties of Lilly.
9.1 Organization and Good Standing. Lilly is a corporation duly
organized and validly existing under the laws of the State of Indiana.
9.2 Corporate Power and Authority; Enforceability. Lilly has the
requisite power and authority (corporate and otherwise) to execute, deliver and
perform this Amendment and to consummate the transactions contemplated hereby.
The execution, delivery and performance by Lilly of this Amendment and the
consummation by Lilly of the transactions contemplated hereby have been duly
authorized by all necessary action (corporate or otherwise) on its part. This
Amendment constitutes a legal, valid and binding obligation of Lilly,
enforceable in accordance with its terms.
9.3 Validity of Contemplated Transactions. The execution, delivery
and performance by Lilly of this Amendment and the consummation by it of the
transactions contemplated hereby do not, and will not (a) violate or contravene
any provision of Lilly's charter or bylaws; (b) violate, breach, conflict with,
constitute a default under, cause the acceleration of any payments pursuant to,
or otherwise impair the good standing, validity, or effectiveness of, any
agreement, contract, indenture, lease, license, or mortgage to which Lilly is a
party or by which Lilly is bound; (c) violate any provision of any law, permit
or court order applicable to Lilly; or (d) require any permit or consent of any
governmental authority to be obtained by Lilly which has not been obtained.
9.4 Litigation Compliance with Laws. There is no litigation
pending or, to Lilly's knowledge, threatened against or related to Lilly nor any
failure to comply with, violation of or any default under, any law, permit or
court order applicable to Lilly, in each case which would have a material
adverse effect on the ability of Lilly to execute, deliver and perform this
Amendment or on the ability of Lilly to consummate the transactions contemplated
hereby.
-9-
<PAGE>
9.5 1933 Act Representations. Lilly is an "accredited investor"
within the meaning of Regulation D as promulgated by the SEC under the 1933 Act.
Lilly has such experience in financial and business matters such that it is
capable of evaluating the merits and risks of purchasing the Shares. Lilly is
acquiring the Shares for its own account, with no present intention of
transferring, distributing or reselling the Shares, or any part thereof, all
without prejudice, however, to the rights of Lilly at any time, in accordance
with this Amendment, lawfully to sell or otherwise dispose of all or any part of
the Shares.
9.6 Governmental Consents. No consent, approval, order or
authorization of, or registration, qualification, designation, declaration or
filing with, any federal, state or local governmental authority in the United
States on the part of Lilly is required in connection with the consummation of
the transactions contemplated by this Amendment.
9.7 Completeness of Disclosure. Neither this Amendment, any
statements made by officers of Lilly nor any instruments or certificates made or
delivered by Lilly in connection herewith contains any untrue statement of a
material fact or omits to state a material fact necessary to make the statements
made herein or therein, in light of the circumstances under which they were
made, not misleading and the other documents delivered in connection herewith,
taken as a whole, together with such statements, instruments or certificates do
not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made herein or therein, in light of the
circumstances under which they were made, not misleading.
9.8 Brokers and Finders. Lilly has not employed any broker, finder,
consultant or intermediary in connection with the transactions contemplated by
this Amendment who would be entitled to a broker's, finder's or similar fee or
commission in connection therewith or upon the consummation thereof.
10. Conditions to Closing.
10.1. Conditions to Obligations of Centocor. The obligations of
Centocor to consummate the transactions contemplated by this Amendment at the
Closing shall be subject to the satisfaction or waiver by Centocor on or prior
to the Closing Date of the following conditions:
(a) Accuracy of Representations and Warranties; Performance of
Covenants. Each of the representations and warranties of Lilly contained in
this Amendment shall be true and correct in all material respects when made and
as of the Closing Date, with the same effect as though such representations and
warranties had been made on and as of the Closing Date (except representations
and warranties that are made as of a specific date need be true in all material
respects only as of such date); each of the covenants and agreements of Lilly to
be performed on or prior to the Closing Date shall have been duly performed in
all material respects.
-10-
<PAGE>
(b) No Order. There shall not have been issued and be in effect
any injunction (temporary or permanent), order, decree, judgment of or in any
court or tribunal of competent jurisdiction (an "Order") which prohibits the
consummation of the purchase and sale of the Shares or which materially
restricts Centocor's ability to achieve the benefits of the transactions set
forth in the Amendment.
10.2. Conditions to Obligations of Centocor. The obligations of
Lilly to consummate the transactions contemplated by this Amendment at the
closing shall be subject to the satisfaction or waiver by Lilly on or prior to
the Closing Date of the following conditions:
(a) Accuracy of Representations and Warranties; Performance of
Covenants. Each of the representations and warranties of Centocor contained in
this Amendment shall be true and correct in all material respects when made and
as of the Closing Date, with the same effect as though such representations and
warranties had been made on and as of the Closing Date (except representations
and warranties that are made as of a specific date need be true in all material
respects only as of such date); each of the covenants and agreements of Centocor
to be performed on or prior to the Closing Date shall have been duly performed
in all material respects.
(b) No Order. There shall not have been issued and be in effect
any Order which prohibits the consummation of the purchase and sale of the
Shares or which materially restricts Lilly's ability to achieve the benefits of
the transactions set forth in the Amendment.
(c) Consents. Centocor shall have obtained all consents or
approvals of any third party, if any, which are necessary for or in connection
with the execution and delivery of this Amendment or the performance of Centocor
under this Amendment.
(d) Opinion of Counsel. Lilly shall have received from Duane
Morris & Heckscher, counsel for Centocor, an opinion dated as of the Closing
Date, in form and substance reasonably satisfactory to Lilly as described below
(an opinion of counsel from CNTO's in-house counsel, George D. Hobbs, with
respect to subsections (iii) and (iv) below is satisfactory to Lilly provided
the form and substance of such opinion remains the same as described below):
(i) CNTO is a corporation duly organized, validly existing
and in good standing under the laws of its jurisdiction of incorporation;
(ii) CNTO has the requisite power and authority (corporate
and otherwise) to execute, deliver and perform this Amendment and to consummate
the transactions contemplated hereby. The execution, delivery and performance by
CNTO of this Amendment and the consummation by CNTO of the transactions
contemplated hereby, have been duly authorized by all necessary action
(corporate or otherwise) on its part. This Amendment constitutes a legal, valid
and binding obligation of CNTO, enforceable in accordance with its terms,
-11-
<PAGE>
subject, as to enforcement of remedies, to applicable bankruptcy, insolvency,
reorganization, moratorium or other similar laws affecting creditors' rights
generally and the availability of equitable remedies which are subject to the
discretion of the court before which any proceeding is brought;
(iii) The execution, delivery and performance by CNTO and
CBV of this Amendment, and the consummation by them of the transactions
contemplated hereby, do not, and will not violate or contravene any provision of
CNTO's or CBV's Articles of Incorporation, Charter or bylaws;
(iv) Except as otherwise disclosed herein, in any Schedule
or Exhibit hereto, or set forth in Schedule 8.4 hereto, such counsel is not
aware of any suit, action, proceeding or investigation pending or threatened
against CNTO or CBV or any of its subsidiaries or affiliates, which, if
determined adversely to such parties, would (i) prohibit the execution or
delivery of this Amendment, (ii) prohibit the issuance and sale of the Shares
pursuant to this Amendment, or (iii) have a Material Adverse Effect. To the best
of such counsel's knowledge, except as set forth in Schedule 8.4 hereto, CNTO or
CBV is not the subject of or bound by or otherwise affected by any outstanding
judgments or decrees of any court or governmental agency that would have a
Material Adverse Effect;
(v) The Shares, when issued and delivered to Lilly
pursuant to and in accordance with the terms of this Amendment, (a) will have
been validly issued and will be fully paid and non-assessable, (b) will be free
and clear of any liens, (c) to such counsel's knowledge, will have been issued
without violation of any preemptive or other right to purchase Common Stock, and
(d) based in part on representations of Lilly in this Amendment, be issued in
compliance with all applicable federal and state securities laws; and
(vi) CNTO currently meets the conditions necessary for use
of a registration statement on Form S-3 under the 1933 Act.
11. Indemnification.
(a) In the event of any registration of any of the Shares under the
1933 Act pursuant to this Amendment, Centocor (notwithstanding anything to the
contrary in this Amendment, for purposes of this Section 11, Centocor shall mean
CNTO and CBV each jointly and separately) shall indemnify and hold harmless
Lilly with respect to the sale of such Shares against any losses, claims,
damages or liabilities, joint or several, to which Lilly may become subject
under the 1933 Act or any other statute or at common law, insofar as such
losses, claims, damages or liabilities (or actions in respect thereof) arise out
of or are based upon (i) any alleged untrue statement of any material fact
contained, in any registration statement under which such Shares were registered
under the 1933 Act pursuant to the provisions of Section 7 of this Amendment,
any preliminary prospectus or final prospectus contained therein, or any summary
prospectus issued in connection with any Shares being registered, or any
amendment or supplement thereto, or (ii) any alleged omission to state in any
such document a material fact required to be stated therein or necessary to make
the statements
-12-
<PAGE>
therein not misleading, and shall reimburse Lilly for any legal or other
expenses reasonably incurred by Lilly in connection with investigating or
defending any such loss, claim, damage, liability or action; provided, however,
that Centocor shall not be liable to Lilly in any such case to the extent that
any such loss, claim damage or liability arises out of or is based upon (i) any
alleged untrue statements or alleged omissions made in such registration
statement, prospectus, summary prospectus, prospectus, or amendment or
supplement thereto that is made in reliance upon and in conformity with written
information furnished to Centocor by Lilly, as the case may be, specifically for
use therein, or (ii) any alleged untrue statement or alleged omission in a
preliminary prospectus if the final prospectus (or the final prospectus as
amended or supplemented before confirmation of sale) corrects such alleged
untrue statement or omission and a copy of the final prospectus (as so amended
or supplemented) was not sent or given to the person or persons alleging such
untrue statement or omission at or before the confirmation of any sale thereto
in any case where such delivery is required by the 1933 Act, unless the failure
to deliver the final prospectus (as so amended or supplemented) was the result
of non-compliance by Centocor with the requirements of the 1933 Act pertaining
to furnishing to each seller such numbers of copies of prospectus, including a
preliminary prospectus, and such other documents, as such seller may reasonably
request in order to facilitate the public sale or other disposition of the
Shares owned by such seller. Such indemnity shall remain in full force and
effect regardless of any investigation made by or on behalf of Lilly, and shall
survive transfer of such Shares by Lilly.
(b) Lilly shall indemnify and hold harmless, Centocor, its
directors and officers, and each other person, if any, who controls Centocor,
against any losses, claims, damages or liabilities, joint or several, to which
Centocor or any such director or officer, or any controlling person of Centocor
may become subject under the 1933 Act or any other statute or at common law,
insofar as such losses, claims, damages or liabilities (or actions in respect
thereof) arise out of or are based upon (i) any alleged untrue statement or any
material fact contained in any registration statement under which Shares
belonging to Lilly were registered under the 1933 Act, pursuant to Section 7 of
this Amendment, any preliminary prospectus or final prospectus contained
therein, or any summary prospectus issued in connection with any such Shares
being registered, or any amendment or supplement thereto, or (ii) any alleged
omission to state in any such document a material fact required to be stated
therein or necessary to make the statements therein not misleading, in the case
of (i) or (ii) to the extent, but only to the extent, that such alleged untrue
statement or alleged omission was made in such registration statement,
preliminary prospectus, summary prospectus, prospectus, amendment or supplement
in reliance upon and in conformity with written information furnished to
Centocor by Lilly specifically for use therein, and then only to the extent that
such alleged untrue statements of alleged omissions by Lilly were not based on
the authority of an expert as to which Lilly had no reasonable ground to
believe, and did not believe, that the statements made on the authority of such
expert were untrue or that there was an omission to state a material fact, and
shall reimburse Centocor or such director, officer, or controlling person of
Centocor for any legal or any other expenses reasonably incurred in connection
with investigating or defending any such loss, claim,
-13-
<PAGE>
damage, liability or action. Notwithstanding the provisions of this Section
11(b), the aggregate liability of Lilly pursuant to the foregoing indemnity
provisions shall not exceed the net proceeds (before deducting expenses)
received by Lilly and its affiliates from the Shares sold by it pursuant to such
registration.
(c) Indemnification similar to that specified in subparagraphs
(a) and (b) of this Section 11 shall be given by Centocor and Lilly (with such
modifications as shall be appropriate) covered by any registration or other
qualification of Shares under any federal or state securities law or regulation
other than the 1933 Act with respect to any such registration or other
qualification effected pursuant to the provisions of this Amendment.
(d) If the Indemnification provided for in this Section 11 is
held by a court of competent jurisdiction to be unavailable to an Indemnified
Party (hereinafter defined as in Section 11(e) hereof) with respect to any loss,
liability, claim, damage, or expense referred to therein, then the Indemnifying
Party (hereinafter defined as in Section 11(e) hereof) in lieu of indemnifying
such Indemnified Party hereunder, shall contribute to the amount paid or payable
by such Indemnified Party as a result of such loss, liability, claim, damage, or
expense in such proportion as is appropriate to reflect the relative fault of
the Indemnifying Party on the one hand and of the Indemnified Party on the other
in connection with the statements or omissions that resulted in such loss,
liability, claim, damage, or expense as well as any other relevant equitable
considerations. The relative fault of the Indemnifying Party and of the
Indemnified Party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission to state a material fact relates to information supplied by the
Indemnifying Party or by the Indemnified Party and the parties' relative intent,
knowledge, access to information, and opportunity to correct or prevent such
statement or omission.
(e) In the event Centocor or any holder of Shares receives a
complaint, claim or other notice of any loss, claim or damage, liability or act,
giving rise to a claim for indemnification or contribution under subparagraphs
(a), (b), (c) or (d) of this Section 11, the person claiming indemnification
(the "Indemnified Party") under any such subparagraph shall promptly notify the
person against whom indemnification is sought (the "Indemnifying Party") or such
complaint, notice, claim or action, and the Indemnifying Party shall have the
right to investigate and defend any such loss, claim, damage, liability or
action. The Indemnified Party shall have the right to employ separate counsel
in any such action and to participate in the defense thereof but the fees and
expenses of such counsel shall not be at the expense of the Indemnifying Party.
In no event shall the Indemnifying Party be obligated to indemnify any person
for any settlement of any claim or action effected without the Indemnifying
Party's written consent.
12. Regulatory Compliance. Centocor shall comply with all applicable
regulatory requirements, including, without limitation, those provisions of
Article VIII of the Agreement relating to reporting Adverse Drug Events and
communications with regulatory agencies with respect to ReoPro in Japan, and if
-14-
<PAGE>
Centocor enters into any agreement with a third party relating to ReoPro in
Japan, Centocor shall use its best efforts to cause such third party to comply
with such requirements, including, if applicable, reporting of Adverse Drug
Events to Lilly.
13. Trademark Assignment. Lilly hereby agrees to use its best efforts to
take any and all actions necessary to promptly transfer to Centocor, Lilly's
rights to the Japanese trademark application No. 89722/94 pertaining to "ReoPro"
in Japan, together with all goodwill associated therewith for use only in Japan.
14. Miscellaneous.
(a) All references to the "Agreement" in any documents and
instruments executed by the parties in connection with the Agreement, shall be
deemed to refer to the Agreement as the same has been amended through the date
hereof, and as the same may be amended in the future.
(b) The parties hereto agree to do such further acts and to execute
and deliver to each other such additional agreements, instruments and documents
as may be reasonably required to carry out the purpose of this Amendment.
(c) This Amendment may be executed in any number of counterparts and
each such counterpart shall be deemed an original, but all such counterparts
shall constitute but one and the same agreement.
(d) The Agreement and this Amendment may be modified or amended by
the parties hereto only by a written agreement executed by the party against
whom a change is to be enforced.
(e) This Amendment shall be governed by and construed in accordance
with the internal laws of the Commonwealth of Pennsylvania, without regard to
conflicts of laws principles.
15. Ratification and Confirmation. Except as amended hereby, all of the
terms and provisions of the Agreement and documents executed in accordance
therewith shall remain in full force and effect and, except as expressly amended
hereby, are hereby ratified and confirmed.
-15-
<PAGE>
IN WITNESS WHEREOF, the undersigned have caused this Amendment to be
executed by their duly authorized officers on the date first above written.
CENTOCOR, INC.
/s/ Dominic J. Caruso
- ------------------------------------------------
By: Dominic J. Caruso
Title: Vice President of Finance and
Chief Financial Officer
CENTOCOR B.V.
/s/ David P. Holveck
- ------------------------------------------------
By: David P. Holveck
Title: President and Chief Executive Officer of Centocor Inc.
and Managing Director, Centocor, B.V.
ELI LILLY AND COMPANY
/s/ Sidney Taurel
- ------------------------------------------------
By: Sidney Taurel
Title: President and Chief Operating Officer
-16-
<PAGE>
Exhibit 23
Consent of Independent Auditors
-------------------------------
The Board of Directors
Centocor, Inc.:
We consent to incorporation by reference in Registration Statement Nos.
33-35729,33-16286, 33-7311, 33-23481, 33-44231, 33-29142 and 333-07829 on Form
S-3 and in Registration Statement Nos. 33-35731, 2-86486, 33-35730, 33-00167,
33-16285, 33-16284 and 33-23480 on Form S-8 of Centocor, Inc. of our report
dated January 31, 1997 relating to the balance sheets of Centocor Partners III,
L.P. as of December 31, 1996 and 1995 and the related statements of operations,
cash flows and partners' capital for each of the years in the three-year period
ended December 31, 1996, which report appears in the December 31, 1996 Annual
Report on Form 10-K/A of Centocor, Inc.
/s/ KPMG Peat Marwick LLP
Philadelphia, Pennsylvania
May 14, 1998
